Engineered cleavage half-domains

Details Engineered cleavage half-domains Engineered cleavage half-domains

2009-06-23

2011-10-11

Fronda, Christian (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S069100, C435S252300, C435S320100, C530S350000, C536S023100, C536S023200

Reexamination Certificate

active

08034598

ABSTRACT:
Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.

REFERENCES:
patent: 4186183 (1980-01-01), Steck et al.
patent: 4217344 (1980-08-01), Vanlerberghe et al.
patent: 4235871 (1980-11-01), Papahadjopolous et al.
patent: 4261975 (1981-04-01), Fullerton et al.
patent: 4485054 (1984-11-01), Mezei et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4774085 (1988-09-01), Fidler
patent: 4837028 (1989-06-01), Allen
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5049386 (1991-09-01), Eppstein et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5176996 (1993-01-01), Hogan et al.
patent: 5422251 (1995-06-01), Fresco
patent: 5585245 (1996-12-01), Johnsson et al.
patent: 5643758 (1997-07-01), Guan et al.
patent: 5789538 (1998-08-01), Rebar et al.
patent: 5925523 (1999-07-01), Dove et al.
patent: 5928638 (1999-07-01), Uchida et al.
patent: 6007988 (1999-12-01), Choo et al.
patent: 6013453 (2000-01-01), Choo et al.
patent: 6140081 (2000-10-01), Barbas
patent: 6200759 (2001-03-01), Dove et al.
patent: 6453242 (2002-09-01), Eisenberg et al.
patent: 6503717 (2003-01-01), Case et al.
patent: 6534261 (2003-03-01), Cox et al.
patent: 6599692 (2003-07-01), Case et al.
patent: 6607882 (2003-08-01), Cox, III et al.
patent: 6689558 (2004-02-01), Case
patent: 6824978 (2004-11-01), Cox, III et al.
patent: 6933113 (2005-08-01), Case et al.
patent: 6979539 (2005-12-01), Cox, III et al.
patent: 7013219 (2006-03-01), Case et al.
patent: 7163824 (2007-01-01), Cox, III et al.
patent: 2003/0232410 (2003-12-01), Liljedahl et al.
patent: 2005/0026157 (2005-02-01), Baltimore
patent: 2005/0064474 (2005-03-01), Urnov et al.
patent: 2005/0208489 (2005-09-01), Carroll
patent: 2006/0063231 (2006-03-01), Li et al.
patent: 2006/0188987 (2006-08-01), Guschan et al.
patent: WO 91/16024 (1991-10-01), None
patent: WO 91/17424 (1991-11-01), None
patent: WO 93/24641 (1993-02-01), None
patent: WO 95/19431 (1995-07-01), None
patent: WO 96/06166 (1996-02-01), None
patent: WO 98/44350 (1998-10-01), None
patent: WO 98/53057 (1998-11-01), None
patent: WO 98/53058 (1998-11-01), None
patent: WO 98/53059 (1998-11-01), None
patent: WO 98/53060 (1998-11-01), None
patent: WO 98/54311 (1998-12-01), None
patent: WO 00/27878 (2000-05-01), None
patent: WO 01/60970 (2001-08-01), None
patent: WO 01/88197 (2001-11-01), None
patent: WO 02/16536 (2002-02-01), None
patent: WO 02/099084 (2002-12-01), None
patent: WO 03/016496 (2003-02-01), None
patent: 2005/014791 (2005-01-01), None
patent: WO 2005/084190 (2005-09-01), None
patent: WO 2007/014275 (2007-01-01), None
Seffernick et al. J Bacteriol. Apr. 2001; 183 (8): 2405-10.
Witkowski et al. Biochemistry. Sep. 7, 1999; 38(36): 11643-50.
Ahmad, et al., “Antibody-Mediated Specific Binding and Cytotoxicity of Liposome-Entrapped Doxorubicin to Lung Cancer Cells In Vitro,”Cancer Res52(17):4817-4820 (1992).
Alvarez, et al. “A Phase I Study of Recombinant Adenovirus Vector-Mediated Intraperitoneal Delivery of Herpes Simplex Virus Thymidine Kinase (HSV-TK) Gene and Intravenous Ganciclovir for Previously Treated Ovarian and Extraovarian Cancer Patients,”Hum. Gene Ther. 8(5):597-613 (1997).
Anderson, et al., “Phosphorylation and Rapid Relocalization of 53BP1 to Nuclear FOCI Upon DNA Damage,”Mol Cell Biol21:1719-1729 (2001).
Anderson, “Human Gene Therapy,”Science256(5058):808-813 (1992).
Atwell, et al., “Stable Heterodimers From Remodeling the Domain Interface of a Homodimer Using a Phage Display Library,”J Mol Biol270:26-35 (1997).
Behr, et al., “Gene Transfer With Synthetic Cationic Amphiphiles: Prospects for Gene Therapy,”Bioconjug. Chem. 5(5):382-389 (1994).
Bitinate, et al., “FOKI Dimerization is Required for DNA Cleavage,”PNAS USA95:10570-10575 (1998).
Blaese, et al., “Vectors in Cancer Therapy: How Will They Deliver?”Cancer Gene Therapy2:291-297 (1995).
Blaese, et al., “T Lymphocyte-Directed Gene Therapy for ADA-SCID: Initial Trial Results After 4 Years,”Science270(5235):475-480 (1995).
Bolon, et al., “Specificity Versus Stability in Computational Protein Design,”PNAS USA102:12724-12729 (2005).
Buchscachher, et al., “Human Immunodeficiency Virus Vectors for Inducible Expression of Foreign Genes,”J Virol66(5):2731-2739 (1992).
Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,”Science270(5235):404-410 (1995).
Dillon, “Regulating Gene Expression in Gene Therapy,”TIBTECH11(51:167-175 (1993).
Dranoff, et al., “A Phase I Study of Vaccination With Autologous, Irradiated Melanoma Cells Engineered to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor,”Hum Gene Ther. 8(1):111-112 (1997).
Dull, et al., “A Third-Generation Lentivirus Vector With a Conditional Packaging System,”J. Virol. 72:8463-8471 (1998).
Dunbar, et al., “Retrovirally Marked CD34-Enriched Peripheral Blood and Bone Marrow Cells Contribute to Long-Term Engraftment After Autologous Transplantation,”Blood85(11):3048-3057 (1995).
Ellem, et al., “A Case Report: Immune Responses and Clinical Course of the First Human Use of Granulocyte/Macrophage-Colony-Stimulating-Factor-Transduced Autologous Melanoma Cells for Immunotherapy,”Cancer Immunol Immunother. 44(1):10-20 (1997).
Fields, et al., “A Novel Genetic System to Detect Protein-Protein Interactions,”Nature340:245-246 (1989).
Follenzi, et al., “Gene Transfer by Lentiviral Vectors is Limited by Nuclear Translocation and Rescued by HIV-1 POL Sequences,”Nature Genetics25:217-222 (2000).
Gao, et al., “Cationic Liposome-Mediated Gene Transfer,”Gene Therapy2:710-722 (1995).
Gribskov, et al., “SIGMA Factors FromE. coli, B. Subtilis, Phage SP01, and Phage T4 are Homologous Proteins,”Nucl Acids Res. 14(6):6745-6763 (1986).
Han, et al., “Ligand-Directed Retroviral Targeting of Human Breast Cancer Cells,”PNAS USA92:9747-9751 (1995).
Havranek, et al., “Automated Design of Specificity in Molecular Recognition,”Nat Struct Biol10-45-52 (2003).
Hermonat, et al., “Use of Adeno-Associated Virus as a Mammalian DNA Cloning Vector: Transduction of Neomycin Resistance Into Mammalian Tissue Culture Cells,”PNAS81:6466-6470 (1984).
Inaba, et al., “Generation of Large Numbers of Dendritic Cells From Mouse Bone Marrow Cultures Supplemented With Granulocyte/Macrophage Colony-Stimulating Factor,”J Exp Med176:1693-1702 (1992).
Jeggo, et al., “DNA Breakage and Repair,”Adv Genet38:185-218 (1998).
Johann, et al., “GLVR1, A Receptor for Gibbon Ape Leukemia Virus, Is Homologous to a Phosphate Permease of Neurospora Crassa and is Expressed at High Levels in the Brain and Thymus,”J Virol66:1635-1640 (1992).
Kaye, et al., “A Single Amino Acid Substitution Results in a Retinoblastoma Protein Defective in Phosphorylation and Oncoprotein Binding,”PNAS USA87:6922-6926 (1990).
Kearns, et al., “Recombinant Adeno-Associated Virus (AAV-CFTR) Vectors Do Not Integrate in a Site-Specific Fashion in an Immortalized Epithelial Cell Line,”Gene Ther. 9:748-755 (1996).
Kohn, et al., “Engraftment of Gene-Modified Umbilical Cord Blood Cells in Neonates With Adenosine Deaminase Deficiency,”Nat Med1:1017-1102 (1995).
Kotin, “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy,”Hum. Gene Ther. 5:793-801 (1994).
Kremer & Perricaudet, “Adenovirus and Adeno-Associated Virus Mediated Gene Transfer,”British Medical Bulletin51(1):31-44

Affiliated with

Also associated with

Rating

Engineered cleavage half-domains does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Engineered cleavage half-domains, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Engineered cleavage half-domains will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4277174